Author

R. Winkler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. F. Stenzel· 1 shared A. Gluck· 1 shared A. Nachshon· 1 shared A. Peace· 1 shared A. Pinharanda· 1 shared A. W. Ashbrook· 1 shared A.-M. Schaffer· 1 shared A.-S. Mägdefrau· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. F. Stenzel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A genome-wide arrayed CRISPR screen identifies PLSCR1 as an intrinsic barrier to SARS-CoV-2 entry that recent virus variants have evolved to resist

J. Le Pen, G. Paniccia, V. Kinast, M. Moncada-Velez, A. W. Ashbrook, M. Bauer, H.- H. Hoffmann, A. Pinharanda, I. Ricardo-Lax, A. F. Stenzel, E. A. Rosado-Olivieri, K. H. Dinnon, W. C. Doyle, C. A. Freije, S.-H. Hong, , C. M. Rice

The paper identifies PLSCR1 as a host factor restricting SARS-CoV-2 entry, which recent variants have evolved to bypass, through a CRISPR screen and integration of genetic studies.

bioRxiv · Feb 16, 2024Immunology

Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition

R. Winkler, A.-S. Mägdefrau, E.-M. Piskor, M. Kleemann, M. Beyer, K. Linke, L. Hansen, A.-M. Schaffer, M. E. Hoffmann, S. Poepsel, F. Heyd, P. Beli, T. Möröy, S. Mahboobi, O. H. Krämer, C. Kosan

This study shows that inhibiting HDAC6 with Marbostat-100 reduces MYC levels and prevents lymphomagenesis in a mouse model of MYC-induced B-cell lymphoma.

Oncogene · Sep 6, 2022Peer-reviewedCancer Biology

SARS-CoV-2 utilizes a multipronged strategy to suppress host protein synthesis

Y. Finkel, A. Gluck, R. Winkler, A. Nachshon, O. Mizrahi, Y. Lubelsky, B. Zuckerman, B. Slobodin, Y. Yahalom-Ronen, H. Tamir, I. Ulitsky, T. Israely, N. Paran, M. Schwartz, N. Stern-Ginossar

This study identifies how SARS-CoV-2 suppresses host protein synthesis through global translation reduction, mRNA degradation, and impaired translation of immune-related transcripts.

bioRxiv · Nov 25, 2020Microbiology